Despite the disappointing late-stage results in non-small cell lung cancer, Jefferies analyst Stephen Barker contends the likelihood of FDA approval “remains high” for the experimental antibody-drug conjugate, though the regulator is now more likely to convene an advisory committee.
Tag Archive for: antibody-drug conjugates (ADCs)
Mersana Therapeutics Inc. said on Thursday it had signed a deal for developing cancer drugs with Germany’s Merck KGaA that has the potential to generate up to $800 million in milestone payments.
Merck’s bid to buy the cancer-focused Seagen has hit a roadblock after the two companies failed to agree on a price, according to a Bloomberg report published Friday, citing sources familiar with the matter.